Cell : The Lancet - Translational Medicine

Program

Day 1 - Sunday, 3 November 2013
WELCOME AND INTRODUCTION
11:00-13:00 Registration
13:00-13:15 Welcome and Introduction
E. Marcus, CEO of Cell Press and Editor of Cell, USA
R. Horton, Editor-in-Chief, The Lancet, UK
13:15-14:00 Keynote Address: Achieving an AIDS-free World: Scientific Advances and Public Health Implementation
A. S. Fauci, National Institute of Allergy and Infectious Diseases, USA
Session 1  TARGETING THE RESERVOIRS & WORKING TOWARDS A CURE
Chair: R. Siliciano, Johns Hopkins University, USA
14:00-14:05 Setting the Scene
R. Siliciano, Johns Hopkins University, USA
14:05-14:30 HIV Latency: a Drug Discovery Perspective
D. Hazuda, Merck Research Labs, USA
14:30-14:55 Early Development and Testing of Tools for Cure
D. Margolis, University of North Carolina, USA
14:55-15:20 A New Potential Approach for Attacking the Latent HIV Reservoir
W. C. Greene, Gladstone Institutes, USA
15:20-15:50 REFRESHMENT BREAK
15:50-16:15 Measurement and Mechanism of HIV Persistence: Challenges of Retroviral Biology
J. Coffin, Tufts University, USA
16:15-16:40 Potential Role of Graft-Versus-Host Reaction in Reducing the HIV-1 Reservoir
D. R. Kuritzkes, Harvard Medical School, USA
16:40-17:25 Panel Discussion: Which of these suggested routes to a cure are most feasible to pursue?
17:25-17:55 Oral Poster Session 1
17:55-19:10 DRINKS RECEPTION
Day 2 - Monday, 4 November 2013
Session 2  VACCINES & HARNESSING THE IMMUNE RESPONSE
Chair: E. Marcus, CEO of Cell Press and Editor of Cell, USA 
08.00-08:05 Setting the Scene
E. Marcus, CEO of Cell Press and Editor of Cell, USA
08.05-08:30 Preventing the Spread of HIV with Antibody Genes
D. Baltimore, California Institute of Technology, USA
08:30-08:55 Toward an HIV Vaccine: What Can the Virus Reveal?
B. D. Walker, Ragon Institute of MGH, MIT and Harvard, USA
08:55-09:20 Human Antibodies to HIV in Vaccine Development and Therapy
M. C. Nussenzweig, Howard Hughes Medical Institute, New York, USA
09:20-09:50 REFRESHMENT BREAK
09:50-10:15 Strategies for HIV Vaccine Design
D. R. Burton, The Scripps Research Institute, Ragon Institute of MGH, MIT and Harvard, USA
10.15-10:40 Defining relevant immune targets for protection against HIV-1 infection by vaccination
M. J. McElrath, Fred Hutchinson Cancer Research Center, USA
10:40-11:25 Panel Discussion: What kind of host immune response do we need to generate to have an effective vaccine?
11:25-11:55 Oral Poster Session 2
11:55-12:55 LUNCH
Session 3  Antiretrovirals for Primary & Secondary HIV Prevention
Chair: K. Mayer, The Fenway Institute, USA
13:00-13:05 Setting the Scene
K. Mayer, The Fenway Institute, USA
13:05-13:25 Antiretroviral Treatment of HIV-1 Prevents Transmission of HIV-1: Where Do We Go From Here?
M. S. Cohen, University of North Carolina, USA
13:25-13:45 ART for Prevention: Key Unanswered Questions
W. El-Sadr, Columbia University, USA
13:45-14:05 What Will It Take To Achieve an AIDS-Free Generation in Uganda?
D. Serwadda, Makerere University School of Public Health, Uganda
14:05-14:50 Panel Discussion: Test and treat as a global strategy
14:50-15:20 REFRESHMENT BREAK
15:20-15:40
PrEP: Evidence, Questions, and Implementation Priorities
C. Celum, University of Washington, USA
15:40-16:00 Making Pharmacological Sense of the Successes and Failures Among PrEP Clinical Trials
C. Hendrix, Johns Hopkins University, USA
16:00-16:20 PrEP Pipeline and Multipurpose Prevention Technologies
G. Doncel, CONRAD, USA
16:20-17:05 Panel Discussion: Chemoprophylaxis
17:05-17:35 Debate: How to prevent epidemics worldwide?
19:30 Meet the Speakers Dinner – Ticket holders only
After Dinner Speaker: T. Brown, Timothy Ray Brown Foundation of the World AIDS Institute, USA
Day 3 - Tuesday, 5 November 2013
Session 4 LONG TERM CONSEQUENCES OF LIVING WITH HIV: COMORBIDITIES & AGING
Chair: J.A. Levy, University of California San Francisco, USA
08.00-08:05 Setting the Scene
J. A. Levy, University of California, San Francisco, USA
08.05-08:30 The End of AIDS: HIV Infection as a Chronic Disease
S. G. Deeks, University of California, San Francisco, USA
08:30-08:55 Differences in Pathogen-Specific T cell Susceptibility to HIV Influence the Natural History of Opportunistic Infections
R. Koup, National Institutes of Health, USA
08:55-09:20


Risk of Serious Disease and Death in People with HIV Viral Suppression on ART: An Epidemiologic Perspective
A. Phillips, University College London, UK
09:20-09:45 HIV and Aging: Challenges for Prevention and Case Management
F. Dabis, Bordeaux School of Public Health, France
09:45-10:10 Long Term Complications of HIV Infection and Treatment: Reducing Risk
J. S. Currier, University of California, Los Angeles, USA
10.10-10:40 REFRESHMENT BREAK
10:40-11:05 HIV-Associated Neurocognitive Disorder in the cART Era
D. B. Clifford, Washington University School of Medicine, USA
11:05-11:30 Long Term Impact of Antiretroviral Therapy in Resource Limited Settings
N. Kumarasamy, YRG Centre for AIDS Research and Education, India
11:30-12:15 Panel Discussion: What’s the biggest risk for long term survivors of HIV?
12:15-13:15 LUNCH
Session 5 CHALLENGE DISCUSSION: WHAT WILL IT TAKE TO ACHIEVE AN AIDS-FREE WORLD?
Chair: R. HORTON, Editor-in-Chief, The Lancet, UK
13:15-14:45

F. Barré-Sinoussi, Institut Pasteur, France
J. A. Levy, University of California, San Francisco, USA
L. Corey, Fred Hutchinson Cancer Research Center, USA
S. Swaminathan, National Institute for Research in Tuberculosis, India
E. Bukusi, Kenya Medical Research Institute, Kenya
D. Evans, Project Inform, USA
E. Goosby, PEPFAR, USA
S. Becker, Deputy Director, HIV/TB, Bill and Melinda Gates Foundation, USA
J.D. Auerbach, University of California, San Francisco, USA

14:45-15:15 REFRESHMENT BREAK
15:15-15:40 Conference Summing Up
R. Siliciano, Johns Hopkins University, USA K. Mayer, The Fenway Institute, USA
15:40-16:00 Closing Remarks
E. Marcus, CEO of Cell Press and Editor of Cell, USA
R. Horton, Editor-in-Chief, The Lancet, UK

 

Organized by

Elsevier
Journal - The Lancet
Journal - Cell
Elsevier

Partners

Timothy Ray Brown
World AIDS Institute